Search results for "leiomyosarcoma"

showing 10 items of 29 documents

Bone metastases in soft tissue sarcoma patients: A survey of natural, prognostic value, and treatment.

2012

10063 Background: Given the limited data currently available, we surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). Methods: This retrospective, multicenter, observational study evaluated data from 135 patients with STS metastatic to the bone who presented between 2001 and 2011. For all patients, we recorded the primary tumor histological subtype, bone metastases characteristics (onset, site), type of treatment received (surgery, radiotherapy, zoledronic acid), type and frequency of skeletal related events (SRE) and disease outcome. Results: The most represented histological subtypes among the enrolled patients were leiomyosarcoma (27%), angi…

LeiomyosarcomaCancer Researchmedicine.medical_specialtybusiness.industrySoft tissue sarcomamedicine.medical_treatmentmedicine.diseasePrimary tumorSurgeryRadiation therapyZoledronic acidmedicine.anatomical_structureOncologymedicineAngiosarcomaSpindle cell sarcomabusinessPelvismedicine.drugJournal of Clinical Oncology
researchProduct

Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.

2016

11062Background: Human equilibrative nucleoside transporter 1 (hENT1) is the major gemcitabine transporter into cells. Gemcitabine is an active drug in different sarcoma subtypes including leiomyos...

LeiomyosarcomaDrugCancer Researchbiologybusiness.industrymedia_common.quotation_subjectTransporterEquilibrative nucleoside transporter 1medicine.diseaseGemcitabineOncologybiology.proteinCancer researchMedicineAngiosarcomaSarcomabusinessmedicine.drugmedia_commonJournal of Clinical Oncology
researchProduct

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from th…

2016

[Background] To report on long-term results of a phase 3 trial comparing three versus five cycles of adjuvant chemotherapy (CT) with full-dose epirubicin+ifosfamide in high-risk soft tissue sarcomas (STS).

LeiomyosarcomaMale0301 basic medicinesarcomaSurvivalmedicine.medical_treatment0302 clinical medicineRisk FactorsQuality of surgeryNeoadjuvant therapySoft tissue sarcomaIfosfamideresponseSoft tissue sarcomaResponseSarcomaHematologyMiddle AgedPrognosisadjuvant chemotherapyTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesissoft tissue sarcomaFemaleSarcomaadjuvant chemotherapy; quality of surgery; response; sarcoma; soft tissue sarcoma; survivalmedicine.drugEpirubicinAdultLeiomyosarcomamedicine.medical_specialtyPreoperative caresurvivalDisease-Free Survival03 medical and health sciencesmedicineHumansAgedbusiness.industrymedicine.diseaseSurgeryAdjuvant chemotherapyRegimen030104 developmental biologybusinessquality of surgeryFollow-Up Studies
researchProduct

Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma.

2017

International audience; Purpose. - Spermatic cord sarcoma is a rare disease, which management remains controversial due to the lack of guidelines. The standard therapeutic approach is surgical: wide soft-tissue resection with radical inguinal orchidectomy, The diagnosis is made during the analysis of the specimen. The high rate of local recurrence indicates adjuvant radiotherapy of the tumor bed. The aim of this series is to determine the efficacy and safety of postoperative intensity-modulated radiotherapy for spermatic cord sarcomas. Patients and methods. - Our series included five consecutive cases of spermatic cord sarcoma treated between 2011 and 2014. The indications for radiotherapy …

LeiomyosarcomaMaleOrgans at Risk[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment030232 urology & nephrologyParatesticular tumor[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine0302 clinical medicineMedicineOrchiectomy[ SDV.IB ] Life Sciences [q-bio]/BioengineeringPatternsFederationRapidarc[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingCancerAged 80 and overSpermatic CordSarcomaRadiotherapy DosageLiposarcomaMiddle AgedRetroperitoneal Sarcoma3. Good healthmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisGenital Neoplasms MaleSoft-Tissue Sarcoma[SDV.IB]Life Sciences [q-bio]/BioengineeringSarcomaRadiodermatitisReoperationmedicine.medical_specialtyPrognostic-Factors[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSpermatic cord03 medical and health sciencesTherapeutic approachHumansRadiology Nuclear Medicine and imagingIMRTAgedRetrospective StudiesRadiotherapybusiness.industryCancermedicine.diseaseRadiation-TherapySurgeryRadiation therapyRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessLigationOrchiectomyRare diseaseFollow-Up StudiesCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
researchProduct

[Gastric leiomyosarcoma: case report and review of literature].

2012

True smooth muscle neoplasms of the wall of digestive tract are rare, in particular in the stomach, and the benign ones are prevalent. We report a case of gastric leiomyosarcoma (LMS) that we observed, diagnosed to a 71 years-old man, with important comorbidities, who had already underwent the amputation of the right lower limb. In consequence of the discovery of anaemia and melaena he underwent an endoscopy of the upper GI tract and CT scan, which showed the presence of a neoformation of the gastric wall, but because of the thrombosis of the common iliac artery and the occurrence of the clinical picture of critical ischaemia, at first the patient underwent the amputation of the left lower …

LeiomyosarcomaMaleleiomyoma leiomyosarcoma mesenchymal neoplasmsSettore MED/18 - Chirurgia GeneraleStomach NeoplasmsHumansAgedLa Clinica terapeutica
researchProduct

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options

2013

Abstract Background We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). Methods This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. Results The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (r…

LeiomyosarcomaOncologymedicine.medical_specialtyMetastasis; bone; sarcoma; prognosis; soft tissuesarcomaBone diseaseSettore MED/06 - Oncologia MedicaSkeletal related eventsboneMetastasisBiphosphonateBiphosphonateInternal medicinemedicineAngiosarcomaSoft tissue sarcomabusiness.industrySoft tissue sarcomaResearchBone metastasesSoft tissueRetrospective cohort studymedicine.diseaseBone metastases Soft tissue sarcoma Skeletal related events BiphosphonateSurgeryOncologySarcomaprognosisbusinesssoft tissue
researchProduct

Radiologie des gastrointestinalen Stromatumors (GIST). Gleichzeitig ein Beitrag zum Carney-Syndrom

2000

Gastrointestinal stromal tumors (GIST) represent an extremely rare group of tumors, which are mostly of smooth muscle origin like leiomyomas, leiomyosarcomas and leiomyoblastomas. With the introduction of immunohistochemical analysis an epitheloid and an autonomic nerve variant can be distinguished. The purpose of this review is to demonstrate the image morphological appearance of these rare tumors together with the pathology based upon a retrospective analysis of five of our own cases since 1997. There are no pathognomonic imaging findings for characterizing a gastrointestinal stromal tumor; however, it should be included in the differential diagnosis if one or multiple large, round or ova…

LeiomyosarcomaPathologymedicine.medical_specialtyGiSTbusiness.industrymedicine.diseaseGastric LeiomyosarcomaParagangliomaPathognomonicmedicineRadiology Nuclear Medicine and imagingStromal tumorDifferential diagnosisbusinessChondromaRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

In regard to “A tale of two clones: Caldesmon staining in the differentiation of cutaneous spindle-cell neoplasms”

2018

LeiomyosarcomaPathologymedicine.medical_specialtyHistologyCellDermatologyH caldesmonPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSmooth musclemedicineHumansHistiocytoma Benign FibrousStaining and LabelingbiologyAtypical fibroxanthomaCell Differentiationmedicine.diseaseStainingCaldesmonmedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinCalmodulin-Binding ProteinsJournal of Cutaneous Pathology
researchProduct

PML down-regulation in soft tissue sarcomas

2010

To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantl…

LeiomyosarcomaPathologymedicine.medical_specialtyPhysiologysoft tissue tumorSettore MED/06 - Oncologia MedicaClinical BiochemistryDown-RegulationLiposarcomaPromyelocytic Leukemia ProteinPleomorphic LiposarcomaPML sarcomasPromyelocytic leukemia proteinmedicineHumanssarcomasneoplasmsMyxoid liposarcomaPMLbiologybusiness.industrySoft tissue sarcomaTumor Suppressor ProteinsNuclear ProteinsSarcomaCell BiologyAnatomymedicine.diseaseImmunohistochemistrySynovial sarcomabody regionsbiology.proteinSarcomabusinessTranscription Factors
researchProduct

Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma

2021

The invasive tumor front (the tumor–host interface) is vitally important in malignant cell progression and metastasis. Tumor cell interactions with resident and infiltrating host cells and with the surrounding extracellular matrix and secreted factors ultimately determine the fate of the tumor. Herein we focus on the invasive tumor front, making an in-depth characterization of reticular fiber scaffolding, infiltrating immune cells, gene expression, and epigenetic profiles of classified aggressive primary uterine adenocarcinomas (24 patients) and leiomyosarcomas (11 patients). Sections of formalin-fixed samples before and after microdissection were scanned and studied. Reticular fiber archit…

LeiomyosarcomaReticular fiberreticular fibersÚter - TumorsQH301-705.5Músculs - Càncer:neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales femeninos::neoplasias uterinas [ENFERMEDADES]extracellular matrix:factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS]:Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms Female::Uterine Neoplasms [DISEASES]BiologyMetastasisMetastasisCell and Developmental BiologyImmune system:neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::leiomiosarcoma [ENFERMEDADES]Càncer d'úterimmune cellsTumor-host interfaceMetàstasimedicineUterine cancer:Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Muscle Tissue::Leiomyosarcoma [DISEASES]tumor microenvironment:Biological Factors::Biomarkers::Biomarkers Tumor [CHEMICALS AND DRUGS]Biology (General)epigenetic profilesMicrodissectionAntimicrobial humoral responseOriginal ResearchTumor microenvironmentMarcadors tumoralsImmune cellsEpigenetic profilesCell BiologyExtracellular matrixmedicine.diseaseEpigenèticaTumor microenvironmentReticular connective tissueCancer researchgene expressionEpigeneticsGene expressionThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)Reticular fiberstumor-host interfaceDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct